Jonathan Milner

Jonathan Milner is the co-founder and current Deputy Chairman of Abcam plc, and a seasoned entrepreneur and investor with a strong focus on UK healthcare and high-tech start-ups. He has invested in and supported over 60 companies and played a key role in taking three technology firms public on AIM.

Jonathan holds a doctorate in Molecular Genetics from the University of Leicester and a degree in Applied Biology from the University of Bath. After post-doctoral research at Bath and later at the University of Cambridge in Professor Tony Kouzarides' lab, where he studied the molecular basis of breast cancer, he identified a need for high-quality antibodies—leading to the founding of Abcam in 1998 with David Cleevely and Professor Kouzarides.

He currently serves as Chairman of Axol Bioscience, Camallergy, and PhoreMost, and as a non-executive director at Syndicate Room, Repositive, Elpis Biomedical, Shift Bioscience, and HealX.

Letters

Abcam Plc - 18-May-2023 | 30-May-2023 | 5-Jun-2023 | 12-Jun-2023 | 20-Jun-2023| 20-Jun-2023| 20-Jun-2023| 20-Jun-2023| 21-Jun-2023| 23-Jun-2023| 16-Aug-2023 | 28-Sep-2023 | 10-Oct-2023 | 1-Nov-2023

Presentations

Abcam Plc - 6-Jun-2023 | 12-Jun-2023 | 16-Oct-2023

Below is a list of company engagements where the filer has filed a Schedule 13D and/or engaged in a proxy campaign. As the filer does not file a Form 13F, current ownership information is not available.